| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1012914721 |
| P356 | DOI | 10.1007/S00198-015-3415-4 |
| P698 | PubMed publication ID | 26576544 |
| P2093 | author name string | J Zwerina | |
| K Klaushofer | |||
| E Zwettler | |||
| H P Dimai | |||
| W Brozek | |||
| B Reichardt | |||
| P2860 | cites work | Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe | Q24646707 |
| Denosumab for prevention of fractures in postmenopausal women with osteoporosis | Q28254528 | ||
| Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis | Q34003925 | ||
| Epidemiology of hip fracture: Worldwide geographic variation. | Q34415451 | ||
| The clinical epidemiology of male osteoporosis: a review of the recent literature | Q34461544 | ||
| Vascular effects of bisphosphonates-a systematic review | Q34468751 | ||
| Zoledronic acid and clinical fractures and mortality after hip fracture | Q34689802 | ||
| Healthy user and related biases in observational studies of preventive interventions: a primer for physicians | Q34799001 | ||
| Bisphosphonates and risk of cardiovascular events: a meta-analysis | Q35462296 | ||
| Incidence and mortality of hip fractures in the United States | Q35541830 | ||
| Pathogenesis of osteoporotic hip fractures | Q35702005 | ||
| Short time-frame from first to second hip fracture in the Funen County Hip Fracture Study. | Q36528575 | ||
| Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells | Q36568751 | ||
| Mortality following hip fracture: trends and geographical variations over the last 40 years | Q37226151 | ||
| Potential mediators of the mortality reduction with zoledronic acid after hip fracture | Q37542295 | ||
| Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates | Q37738185 | ||
| Alternative use of bisphosphonate therapy for rheumatic disease | Q37781074 | ||
| Antifracture efficacy of currently available therapies for postmenopausal osteoporosis | Q37822779 | ||
| Bisphosphonates for post-menopausal osteoporosis: are they all the same? | Q37831768 | ||
| The role of falls in fracture prediction | Q37886784 | ||
| Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry | Q38012357 | ||
| Effects of bone-targeted agents on cancer progression and mortality. | Q38023206 | ||
| Bisphosphonate use and subsequent hip fracture in South Korea. | Q38107388 | ||
| Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis | Q38232951 | ||
| Treatment of post-menopausal osteoporosis: beyond bisphosphonates | Q38246517 | ||
| Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment | Q38286904 | ||
| Trends in hip fracture epidemiology in Australia: possible impact of bisphosphonates and hormone replacement therapy | Q39983093 | ||
| The epidemiology of hip fractures and methods of prevention | Q40684499 | ||
| Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study. | Q42607777 | ||
| Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study | Q42650607 | ||
| Effect of osteoporosis treatment on mortality: a meta-analysis. | Q43191945 | ||
| Hip fracture causes excess mortality owing to cardiovascular and infectious disease in institutionalized older people: a prospective 5-year study | Q43797884 | ||
| Channeling bias in the interpretation of drug effects | Q43822996 | ||
| Risk analysis for second hip fracture in patients after hip fracture surgery: a nationwide population-based study | Q44554541 | ||
| Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study | Q44625223 | ||
| Age-specific incidence of first and second fractures of the hip. | Q44692108 | ||
| Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001. | Q45003700 | ||
| Osteoporotic hip fractures: bisphosphonates sales and observed turning point in trend. A population-based retrospective study. | Q45097608 | ||
| Mortality after hip fracture in Austria 2008-2011. | Q50111825 | ||
| Incidence of second hip fractures. A population-based study | Q50166079 | ||
| Epidemiology of hip fractures in Austria: evidence for a change in the secular trend. | Q51145345 | ||
| Osteoporosis medication and reduced mortality risk in elderly women and men. | Q51607037 | ||
| Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study | Q60777432 | ||
| Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials | Q79691425 | ||
| Oral bisphosphonates are associated with reduced mortality after hip fracture | Q82321542 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 387-396 | |
| P577 | publication date | 2015-11-17 | |
| P1433 | published in | Osteoporosis International | Q7107640 |
| P1476 | title | Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study | |
| P478 | volume | 27 |
| Q49350663 | Bisphosphonate use after clinical fracture and risk of new fracture |
| Q90264163 | Bisphosphonate use after clinical fracture and risk of new fracture: response to comments by Wu et al |
| Q92328918 | Bisphosphonates and mortality: confounding in observational studies? |
| Q51829225 | Can orthogeriatics do more than save lives? |
| Q30235444 | Fracture Burden: What Two and a Half Decades of Dubbo Osteoporosis Epidemiology Study Data Reveal About Clinical Outcomes of Osteoporosis |
| Q90186179 | Incidence and Mortality of Osteoporotic Refractures in Korea according to Nationwide Claims Data |
| Q92930505 | Incidence of Osteoporotic Refractures Following Proximal Humerus Fractures in Adults Aged 50 Years and Older in Korea |
| Q40028030 | Patients With Atypical Femur Fractures Have the Same Mortality as the Background Population--Drug-Channeling Bias, Bisphosphonate Effects, and Public Health Implications |
| Q38764108 | Preceding and subsequent high- and low-trauma fracture patterns-a 13-year epidemiological study in females and males in Austria. |
| Q39109115 | Prescription of anti-osteoporosis medications after hospitalization for hip fracture: a multicentre Italian survey. |
| Q39023035 | Use of proton pump inhibitors and mortality after hip fracture in a nationwide study. |
Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120 Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120
Search more.